Jagsonpal Pharmaceuticals Limited
JAGSNPHARM.BO
Bombay Stock Exchange203.65
INR
+1.30
- -
ISIN
INE048B01035
Return %
Stock
S&P500
1Y
-9.47
26.57
3Y
36.97
76.60
5Y
303.11
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Manish Gupta
- Full Time Employees
- 1,025
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- T-210 J, Shahpur Jat Gurugram India 110049
- IPO Date
- Nov 27, 2001
- Website
- jagsonpal.com
- Similar Companies
- Business
- Jagsonpal Pharmaceuticals Limited is an Indian pharmaceutical company specializing in the manufacturing and marketing of a broad range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Its core products include gynecological drugs, orthopedic medicines, dermatological and pediatric products, allied pharmaceutical formulations such as anti-inflammatory agents, anti-infectives, cardiovascular drugs, vitamins and multimineral capsules, anesthetics, and bulk drugs. The company also offers specialized drugs like allylestrenol, anabolic steroids, anti-tubercular drugs, antiasthmatics, antifungal agents, and oral rehydrating salts, among others. Its product portfolio is diversified across therapeutic segments including gynecology, orthopedics, dermatology, pediatrics, and general healthcare, catering primarily to the Indian market and selectively operating in Bhutan. Founded in 1979 and headquartered in New Delhi, Jagsonpal Pharmaceuticals operates mainly in India with an expanding presence in Bhutan through strategic acquisitions. In recent years, the company has significantly expanded its product portfolio and market reach through acquisitions and strategic partnerships. Notably, in 2024, it acquired the India and Bhutan business of Yash Pharma, adding 33 brands to its portfolio and thereby entering the dermatology and pediatrics segments, a market valued at approximately INR 20,000 crore. This acquisition substantially broadened Jagsonpal’s therapeutic footprint and fortified its position in the Indian pharmaceutical market. Additionally, in 2025, the company signed an agreement to acquire the India business of Resilient Cosmeceuticals to further strengthen its product offerings. Recent organizational changes include the appointment of key senior management personnel such as a new Chief Operating Officer and Chief Financial Officer in 2025, reflecting a focus on operational efficiency and growth management. The company continues to invest in business responsibility and sustainability initiatives, reporting such activities publicly and maintaining compliance with regulatory standards. These strategic moves and acquisitions are aligned with Jagsonpal’s vision to become a multi-segment healthcare business with enhanced growth levers, expanding beyond its traditional gynecology and orthopedics base into high-growth areas like dermatology and pediatrics, leveraging an extensive product portfolio and distribution network across India and select overseas markets.